The present invention relates to a compound represented by the following formula (I): ##STR00001## (wherein, W represents W.sup.A-A.sup.1-W.sup.B- (in which, W.sup.A is substituted or unsubstituted aryl, etc., A.sup.1 is --NR.sup.1--, single bond, --C(O)--, etc., and W.sup.B is substituted or unsubstituted arylene, etc.), R is single bond, --NH--, --OCH.sub.2--, alkenylene, etc., X is --C(O)--, --CH.sub.2--, etc., and M is, for example, the following formula: ##STR00002## (in which, R.sup.11, R.sup.12 and R.sup.13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R.sup.14 is hydrogen or lower alkyl, Y represents --CH.sub.2--O--, etc., Z is substituted or unsubstituted arylene, etc., A.sup.2 is single bond, etc, and R.sup.10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same.This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VLA-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.